HOT NEWS
Genzyme
Genzyme Corp.One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com.

Genzyme RSS Channel

Title Filter     Display # 
# Article Title Hits
1 Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC 246
2 Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen 935
3 Study Meets Primary Endpoint with 25 Percent LDL Reduction in Very High-Risk Patient Population 1060
4 European Commission Approves Genzyme's Mozobil 1340
5 Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease 1611
6 Genzyme Receives Positive Opinion for European Approval of Mozobil 1178
7 Genzyme Reports Solid Financial Results for the First Quarter of 2009 1745
8 European Authorities Approve Larger-Scale Production of Genzyme's Myozyme 1157
9 Strong Fourth Quarter for Genzyme Concludes Productive Year 1103
10 Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth 1158
 
Bookmark and Share